EP2748199A4 - Anti-ox40-antikörper und verfahren zu deren verwendung - Google Patents

Anti-ox40-antikörper und verfahren zu deren verwendung

Info

Publication number
EP2748199A4
EP2748199A4 EP12825007.3A EP12825007A EP2748199A4 EP 2748199 A4 EP2748199 A4 EP 2748199A4 EP 12825007 A EP12825007 A EP 12825007A EP 2748199 A4 EP2748199 A4 EP 2748199A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12825007.3A
Other languages
English (en)
French (fr)
Other versions
EP2748199A1 (de
EP2748199B1 (de
Inventor
Yong-Jun Liu
Kui Shin Voo
Laura Bover
Naoya Tsurushita
J Yun Tso
Shankar Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/048752 external-priority patent/WO2012027328A2/en
Application filed by University of Texas System filed Critical University of Texas System
Publication of EP2748199A1 publication Critical patent/EP2748199A1/de
Publication of EP2748199A4 publication Critical patent/EP2748199A4/de
Application granted granted Critical
Publication of EP2748199B1 publication Critical patent/EP2748199B1/de
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EP12825007.3A 2011-08-23 2012-02-09 Anti-ox40-antikörper und verfahren zu deren verwendung Withdrawn - After Issue EP2748199B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/048752 WO2012027328A2 (en) 2010-08-23 2011-08-23 Anti-ox40 antibodies and methods of using the same
PCT/US2012/024570 WO2013028231A1 (en) 2011-08-23 2012-02-09 Anti-ox40 antibodies and methods of using the same

Publications (3)

Publication Number Publication Date
EP2748199A1 EP2748199A1 (de) 2014-07-02
EP2748199A4 true EP2748199A4 (de) 2015-06-17
EP2748199B1 EP2748199B1 (de) 2019-08-28

Family

ID=47747183

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12825007.3A Withdrawn - After Issue EP2748199B1 (de) 2011-08-23 2012-02-09 Anti-ox40-antikörper und verfahren zu deren verwendung

Country Status (9)

Country Link
EP (1) EP2748199B1 (de)
JP (1) JP6038920B2 (de)
KR (1) KR101685262B1 (de)
CN (1) CN103946238B (de)
AU (2) AU2012299421B2 (de)
CA (1) CA2845810C (de)
RU (1) RU2562874C1 (de)
TN (1) TN2013000076A1 (de)
WO (1) WO2013028231A1 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171312A (en) 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
EP3508215A3 (de) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Erhöhung der antikrebswirkung von immunmodulatorischen fc-fusionsproteinen
SG11201507781VA (en) * 2013-03-18 2015-10-29 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
US11273204B2 (en) 2013-08-08 2022-03-15 Cytune Pharma IL-15 and IL-15RAPLHA sushi domain based immunocytokines
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106132439A (zh) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
JP6702991B2 (ja) 2014-11-03 2020-06-03 ジェネンテック， インコーポレイテッド Ｔ細胞免疫サブセットを検出するためのアッセイ及びその使用の方法
US20160160290A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
RU2017119428A (ru) * 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CA2969888A1 (en) * 2015-01-08 2016-07-14 Biontech Ag Agonistic tnf receptor binding agents
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
KR20180015650A (ko) * 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
WO2017021911A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331917A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen sowie verwendungen und verfahren davon
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
EP3331919A1 (de) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie mit anti-ctla-4-antikörpern
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
JP7034066B2 (ja) 2015-10-02 2022-03-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する二重特異性抗体
US10624974B2 (en) * 2015-10-15 2020-04-21 Dingfu Biotarget Co., Ltd. Anti-OX40 antibody and application thereof
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
EP4015537A1 (de) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
MA52157A (fr) 2015-12-03 2021-02-17 Glaxosmithkline Ip Dev Ltd Dinucléotides cycliques de purine utilisés comme modulateurs de sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
EP3440072B1 (de) 2016-04-07 2020-01-29 GlaxoSmithKline Intellectual Property Development Ltd Als proteinmodulatoren geeignete heterocyclische amide
CR20200045A (es) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
EP3452483B1 (de) 2016-05-05 2020-04-01 GlaxoSmithKline Intellectual Property (No. 2) Limited Verstärker von zeste-homolog-2-inhibitoren
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN109789135A (zh) 2016-07-20 2019-05-21 葛兰素史密斯克莱知识产权发展有限公司 作为perk抑制剂的异喹啉衍生物
EP3494140A1 (de) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos- und anti-pd-1-antikörper-kombinationstherapie
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
AU2017308734A1 (en) 2016-08-12 2019-02-14 Janssen Biotech, Inc. Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them
JP2019530704A (ja) 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド がんの処置のためのアベルマブの投与レジメン
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
KR20190090822A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 요법
AU2017369994A1 (en) 2016-12-01 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
SG10201914126RA (en) * 2016-12-15 2020-02-27 Abbvie Biotherapeutics Inc Anti-ox40 antibodies and their uses
KR20190104048A (ko) 2017-01-06 2019-09-05 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
EP3582855A1 (de) 2017-02-15 2019-12-25 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie zur behandlung von krebs
CA3052767A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN108623685B (zh) * 2017-03-25 2022-07-01 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
EP3635011A1 (de) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie mit icos-agonist und ox40-agonisten zur behandlung von krebs
JP2020522556A (ja) 2017-06-09 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法
CN107266568A (zh) * 2017-07-07 2017-10-20 无锡傲锐东源生物科技有限公司 抗foxp3蛋白单克隆抗体及其用途
CN109232738B (zh) * 2017-07-11 2021-11-09 南京金斯瑞生物科技有限公司 一种抗人ox40单克隆抗体及其应用
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
SG11202004457XA (en) 2017-11-17 2020-06-29 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
EP3737743A1 (de) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US20210137930A1 (en) 2018-02-13 2021-05-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
TW202003555A (zh) 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
BR112020021660A2 (pt) 2018-04-27 2021-02-02 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
US20220033775A1 (en) 2018-11-05 2022-02-03 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathways inhibitors
AU2019374761A1 (en) 2018-11-05 2021-06-10 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN113348180B (zh) * 2018-11-20 2023-05-26 上海开拓者生物医药有限公司 Ox40抗体及其制备方法和应用
EP3898949A1 (de) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Verfahren zur expansion tumorinfiltrierender lymphozyten unter verwendung von manipulierten cytokin-rezeptorenpaaren und deren verwendungen
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3904383A4 (de) * 2018-12-25 2022-08-17 Hanx Biopharmaceutics, Inc Monoklonaler anti-ox40-antikörper und anwendung davon
AU2020214412A1 (en) 2019-02-01 2021-08-12 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
KR20220002336A (ko) 2019-03-29 2022-01-06 미스트 쎄라퓨틱스, 엘엘씨 T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법
CN110003338B (zh) * 2019-04-16 2021-04-23 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用
EP3962493A2 (de) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Verfahren zur modulation der immunreaktivität/konzentration von irf oder sting oder zur behandlung von krebs mit der verabreichung eines sting-modulators und/oder eines purinergischen rezeptormodulators oder eines postzellularen signalisierungsfaktors
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP3969438A1 (de) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinylessigsäurederivate und verfahren zur verwendung
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
CN114245869A (zh) 2019-05-23 2022-03-25 百时美施贵宝公司 监测细胞培养基的方法
EP3976090A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
EP3976831A1 (de) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multitumor-gensignaturen für immunonkologische therapie
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN114222760A (zh) 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 Il1rap结合蛋白
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4011389A1 (de) 2019-08-09 2022-06-15 Riken Kombinierte verwendung von künstlichen hilfsvektorzellen und immunstimulans
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
CN114729049A (zh) 2019-09-27 2022-07-08 葛兰素史密斯克莱知识产权发展有限公司 抗原结合蛋白
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2021108727A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Inc. Method of producing tumor-reactive t cell composition using modulatory agents
EP4073236A1 (de) 2019-12-11 2022-10-19 Iovance Biotherapeutics, Inc. Verfahren zur produktion von tumorinfiltrierenden lymphozyten (tils) und verfahren zur verwendung derselben
CA3162705A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4110799A1 (de) 2020-02-27 2023-01-04 Myst Therapeutics, LLC Verfahren zur ex-vivo-anreicherung und expansion tumorreaktiver t-zellen und zugehörige zusammensetzungen davon
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
EP4146794A1 (de) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Verfahren zur herstellung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody preparations and methods of using them
AU2022230795A1 (en) 2021-03-02 2023-09-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4314060A1 (de) 2021-03-31 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Antigenbindende proteine und kombinationen davon
EP4314068A1 (de) 2021-04-02 2024-02-07 The Regents Of The University Of California Antikörper gegen gespaltenes cdcp1 und verwendungen davon
BR112023021665A2 (pt) 2021-04-19 2023-12-19 Iovance Biotherapeutics Inc Método para tratar um câncer, e, composição
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281072A1 (en) * 2002-06-13 2006-12-14 Bakker Alexander Berthold H Agonistic Binding Molecules to the Human OX40 Receptor
US20090214560A1 (en) * 2007-12-14 2009-08-27 Jing Min Binding molecules to the human ox40 receptor
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20100166740A1 (en) * 2004-09-17 2010-07-01 Roche Palo Alto Llc Anti-OX40L antibodies
US20100196359A1 (en) * 2005-11-25 2010-08-05 Shinichiro Kato Human Monoclonal Antibody Human CD134 (Ox40) and Methods of Making and Using Same
US20100254978A1 (en) * 2009-02-17 2010-10-07 Alastair David Griffiths Lawson Antibody molecules having specificity for human ox40
US20110008368A1 (en) * 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004041A1 (en) * 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP1888639A1 (de) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Verfahren zur schädigung von zellen unter verwendung der effektorfunktion eines anti-dsc2-antikörpers
BRPI0621065A2 (pt) * 2005-12-16 2011-11-29 Genentech Inc anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l
MY171312A (en) * 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281072A1 (en) * 2002-06-13 2006-12-14 Bakker Alexander Berthold H Agonistic Binding Molecules to the Human OX40 Receptor
US20100166740A1 (en) * 2004-09-17 2010-07-01 Roche Palo Alto Llc Anti-OX40L antibodies
US20100196359A1 (en) * 2005-11-25 2010-08-05 Shinichiro Kato Human Monoclonal Antibody Human CD134 (Ox40) and Methods of Making and Using Same
US20110008368A1 (en) * 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20090214560A1 (en) * 2007-12-14 2009-08-27 Jing Min Binding molecules to the human ox40 receptor
US20100254978A1 (en) * 2009-02-17 2010-10-07 Alastair David Griffiths Lawson Antibody molecules having specificity for human ox40

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. J. GOUGH ET AL: "OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor", CANCER RESEARCH, vol. 68, no. 13, 1 July 2008 (2008-07-01), pages 5206 - 5215, XP055186758, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-6484 *
See also references of WO2013028231A1 *
WEINBERG ANDREW D ET AL: "Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 29, no. 6, 1 November 2006 (2006-11-01), pages 575 - 585, XP009115398, ISSN: 1524-9557, DOI: 10.1097/01.CJI.0000211319.00031.FC *
WEINBERG ANDREW D ET AL: "Science gone translational: the OX40 agonist story", IMMUNOLOGICAL REVIEWS, vol. 244, no. Sp. Iss. SI, November 2011 (2011-11-01), pages 218 - 231, XP002739167 *
X. XIAO ET AL: "OX40/OX40L Costimulation Affects Induction of Foxp3+ Regulatory T Cells in Part by Expanding Memory T Cells In Vivo", THE JOURNAL OF IMMUNOLOGY, vol. 181, no. 5, 19 August 2008 (2008-08-19), pages 3193 - 3201, XP055186761, ISSN: 0022-1767, DOI: 10.4049/jimmunol.181.5.3193 *

Also Published As

Publication number Publication date
AU2016200435A1 (en) 2016-02-18
KR20140090976A (ko) 2014-07-18
CA2845810A1 (en) 2013-02-28
AU2012299421A1 (en) 2014-03-06
JP6038920B2 (ja) 2016-12-07
WO2013028231A1 (en) 2013-02-28
CA2845810C (en) 2017-03-28
JP2014526898A (ja) 2014-10-09
RU2562874C1 (ru) 2015-09-10
CN103946238A (zh) 2014-07-23
TN2013000076A1 (en) 2014-06-25
EP2748199A1 (de) 2014-07-02
EP2748199B1 (de) 2019-08-28
CN103946238B (zh) 2016-10-12
AU2012299421B2 (en) 2016-02-04
KR101685262B1 (ko) 2016-12-21
AU2016200435B2 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
HUS2000056I1 (hu) ANTI-PD-L1 ellenanyagok és alkalmazásaik
IL250691A0 (en) Anti-ox40 antibodies and methods of using them
HK1255608A1 (zh) 抗htra1抗體及使用方法
EP2748199A4 (de) Anti-ox40-antikörper und verfahren zu deren verwendung
HK1213581A1 (zh) 抗- 抗體及其使用方法
ZA201308022B (en) Anti-cd40 antibodies and methods of use
EP2771694A4 (de) Monoklonale antikörper und verfahren zu ihrer verwendung
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
EP2611832A4 (de) Anti-cxcl13-antikörper und verfahren zu ihrer verwendung
EP2668210A4 (de) Anti-kit-antikörper und ihre verwendungen
EP2742067A4 (de) Monoklonale fzd10-antikörper und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140321

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150520

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20150511BHEP

Ipc: A61K 39/395 20060101ALI20150511BHEP

Ipc: C12N 15/13 20060101ALI20150511BHEP

Ipc: A61P 35/00 20060101ALI20150511BHEP

Ipc: C12N 15/63 20060101ALI20150511BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TSURUSHITA, NAOYA

Inventor name: LIU, YONG-JUN

Inventor name: KUMAR, SHANKAR

Inventor name: BOVER, LAURA

Inventor name: TSO, J. YUN

Inventor name: VOO, KUI SHIN

17Q First examination report despatched

Effective date: 20170808

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20180615

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20181116

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20190312

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

PUAC Information related to the publication of a b1 document modified or deleted

Free format text: ORIGINAL CODE: 0009299EPPU

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: PK

Free format text: DIE ERTEILUNG WURDE VOM EPA WIDERRUFEN.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1172284

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012063442

Country of ref document: DE

DB1 Publication of patent cancelled

Effective date: 20190823

18W Application withdrawn

Effective date: 20190806

REG Reference to a national code

Ref country code: DE

Ref legal event code: R107

Ref document number: 602012063442

Country of ref document: DE

REG Reference to a national code

Ref country code: LU

Ref legal event code: HK

Effective date: 20190918

REG Reference to a national code

Ref country code: AT

Ref legal event code: REZ

Ref document number: 1172284

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190828